Metamizol Tecnigen (Metamizole Magnesium)

Metamizole magnesium works by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins—key mediators of inflammation, pain, and fever. This action dampens the signaling pathways that generate discomfort and elevated temperature, providing relief without engaging opioid receptors.

The appropriate dose of Metamizol Tecnigen is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, age, and overall health status. Healthcare professionals tailor the regimen to achieve optimal analgesic and antipyretic effects while minimizing risk.

Safety data for Metamizole magnesium in pregnancy and lactation are limited, and the product is not classified in a specific pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under direct medical supervision.

To place an order, submit an enquiry on the Metamizol Tecnigen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with traditional NSAIDs, Metamizol Tecnigen offers potent analgesic and antipyretic effects without the typical cyclo‑oxygenase‑related gastrointestinal irritation. Unlike opioids, it does not act on opioid receptors, reducing the risk of dependence, but it carries a rare risk of severe blood dyscrasias that requires monitoring.

Metamizol Tecnigen should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Metamizol Tecnigen is formulated for oral administration. The tablet or oral dosage form is taken by mouth with water, following the prescriber’s instructions regarding timing, food intake, and any required dose adjustments based on clinical response.

The most serious adverse reactions include agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, anaphylaxis, and significant blood dyscrasias. Patients should be monitored for signs of infection, rash, or allergic response, and immediate medical attention is required if these occur.

Metamizol Tecnigen is contraindicated in individuals with a known hypersensitivity to metamizole or other pyrazolones, those with a history of severe blood dyscrasias, and patients with significant hepatic or renal impairment where risk outweighs benefit. It should also be avoided in pregnancy and lactation unless absolutely necessary.